Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Survivin and leukemia.

Literature DB >> 15540897

Survivin and leukemia.

Abstract

Survivin is a unique member of the inhibitor-of-apoptosis family. Survivin plays a role in the proliferation and survival of normal hematopoietic cells. Survivin expression is aberrantly enhanced in most cancers and hematopoietic malignancies. Survivin is an attractive therapeutic target, and various approaches to targeting survivin have been tested in vitro and in vivo. We review here progress in survivin research.

Entities: Disease

Mesh：

Substances：

Year: 2004 PMID： 15540897 DOI： 10.1532/ijh97.a10408

Source DB: PubMed Journal: Int J Hematol ISSN： 0925-5710 Impact factor: 2.490

63 in total

1. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma.

Authors: D Grossman; J M McNiff; F Li; D C Altieri
Journal: J Invest Dermatol Date: 1999-12 Impact factor: 8.551

2. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia.

Authors: L Granziero; P Ghia; P Circosta; D Gottardi; G Strola; M Geuna; L Montagna; P Piccoli; M Chilosi; F Caligaris-Cappio
Journal: Blood Date: 2001-05-01 Impact factor: 22.113

3. Expression of the antiapoptotic gene survivin in chronic myeloid leukemia.

Authors: Adel Badran; Akira Yoshida; Yuji Wano; Shin Imamura; Yasukazu Kawai; Hiroshi Tsutani; Manabu Inuzuka; Takanori Ueda
Journal: Anticancer Res Date: 2003 Jan-Feb Impact factor: 2.480

4. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis.

Authors: S Fukuda; L M Pelus
Journal: Blood Date: 2001-10-01 Impact factor: 22.113

5. The survivin-like C. elegans BIR-1 protein acts with the Aurora-like kinase AIR-2 to affect chromosomes and the spindle midzone.

Authors: E K Speliotes; A Uren; D Vaux; H R Horvitz
Journal: Mol Cell Date: 2000-08 Impact factor: 17.970

6. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins.

Authors: A M Verhagen; P G Ekert; M Pakusch; J Silke; L M Connolly; G E Reid; R L Moritz; R J Simpson; D L Vaux
Journal: Cell Date: 2000-07-07 Impact factor: 41.582

7. Prognostic significance of survivin expression in diffuse large B-cell lymphomas.

Authors: C Adida; C Haioun; P Gaulard; E Lepage; P Morel; J Briere; H Dombret; F Reyes; J Diebold; C Gisselbrecht; G Salles; D C Altieri; T J Molina
Journal: Blood Date: 2000-09-01 Impact factor: 22.113

8. Down-regulation of survivin expression reversed multidrug resistance in adriamycin-resistant HL-60/ADR cell line.

Authors: Lei Wang; Gui-Mei Zhang; Zuo-Hua Feng
Journal: Acta Pharmacol Sin Date: 2003-12 Impact factor: 6.150

9. Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma.

Authors: Noriyuki Takai; Tami Miyazaki; Masakazu Nishida; Kaei Nasu; Isao Miyakawa
Journal: Cancer Lett Date: 2002-10-08 Impact factor: 8.679

10. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression.

Authors: A Krieg; C Mahotka; T Krieg; H Grabsch; W Müller; S Takeno; C V Suschek; M Heydthausen; H E Gabbert; C D Gerharz
Journal: Br J Cancer Date: 2002-03-04 Impact factor: 7.640

12 in total

1. Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses.

Authors: Hua Li; Shengwen Shao; Jianshu Cai; Danielle Burner; Lingeng Lu; Qiuqiang Chen; Boris Minev; Wenxue Ma
Journal: Immunology Date: 2017-07-27 Impact factor: 7.397

2. Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias.

Authors: R Tibes; K T McDonagh; L Lekakis; J M Bogenberger; S Kim; N Frazer; S Mohrland; D Bassett; R Garcia; K Schroeder; V Shanmugam; J Carpten; R T Hagelstrom; C Beaudry; D Von Hoff; T C Shea
Journal: Invest New Drugs Date: 2014-12-19 Impact factor: 3.850

3. TEL-AML1 regulation of survivin and apoptosis via miRNA-494 and miRNA-320a.

Authors: Christofer Diakos; Sheng Zhong; Yuanyuan Xiao; Mi Zhou; Gisele M Vasconcelos; Gerd Krapf; Ru-Fang Yeh; Shichun Zheng; Michelle Kang; John K Wiencke; Maria S Pombo-de-Oliveira; Renate Panzer-Grümayer; Joseph L Wiemels
Journal: Blood Date: 2010-08-31 Impact factor: 22.113

4. Overexpression of survivin initiates hematologic malignancies in vivo.

Authors: S Small; G Keerthivasan; Z Huang; S Gurbuxani; J D Crispino
Journal: Leukemia Date: 2010-09-30 Impact factor: 11.528

5. Detection and preliminary characterization of CD8+T lymphocytes specific for Wilms' tumor antigen in patients with non-Hodgkin lymphoma.

Authors: Anna Israyelyan; Corinna La Rosa; Weimin Tsai; Teodora Kaltcheva; Tumul Srivastava; Lia Aquino; Jianqiang Li; Young Kim; Joycelynne Palmer; Leanne Streja; David Senitzer; John A Zaia; Andreas Rosenwald; Stephen J Forman; Ryotaro Nakamura; Don J Diamond
Journal: Leuk Lymphoma Date: 2013-04-30

6. Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).

Authors: Harry P Erba; Hamid Sayar; Mark Juckett; Michael Lahn; Valerie Andre; Sophie Callies; Shelly Schmidt; Sunil Kadam; John T Brandt; Dirk Van Bockstaele; Michael Andreeff
Journal: Invest New Drugs Date: 2013-02-10 Impact factor: 3.850